Title: | Repurposing chlorpromazine to treat COVID-19: The reCoVery study |
Authors: | PLAZE M ; ATTALI D ; PETIT AC ; BLATZER M ; SIMON LORIERE E ; VINCKIER F ; CACHAI A ; CHRETIEN F ; GAILLARD R |
In : | ENCEPHALE (48(3), 2020) |
Article on page: | 169-172 |
Languages: | French |
Descriptors: |
SANTEPSY CHLORPROMAZINE ; COMORBIDITE ; CORONAVIRUS ; ESSAI CLINIQUE ; PANDEMIE ; PATHOLOGIE PSYCHIATRIQUE |
Abstract: | The ongoing COVID-19 pandemic has caused approximately 2,350,000 infections worldwide and killed more than 160,000 individuals. In Sainte-Anne Hospital (GHU PARIS Psychiatrie & Neuroscience, Paris, France) we have observed a lower incidence of symptomatic forms of COVID-19 among patients than among our clinical staff. This observation led us to hypothesize that psychotropic drugs could have a prophylactic action against SARS-CoV-2 and protect patients from the symptomatic and virulent forms of this infection, since several of these psychotropic drugs have documented antiviral properties. Chlorpromazine (CPZ), a phenothiazine derivative, is also known for its antiviral activity via the inhibition of clathrin-mediated endocytosis. Recentin vitro studies have reported that CPZ exhibits anti-MERS-CoV and anti-SARS-CoV-1 activity [Extrait du résumé] |